Cytotoxic lesions of the corpus callosum after COVID-19 vaccination

Hiroya Ohara1,2 · Hironori Shimizu1,2 · Takehito Kasamatsu3 · Akihiro Kajita3 · Kenji Uno3 · Khin Wee Lai4 · Balachandar Vellingiri5 · Kazuma Sugie2 · Masako Kinoshita2,6

Received: 27 February 2022 / Accepted: 4 July 2022 / Published online: 9 July 2022
© The Author(s) 2022

Abstract
A 23-year-old previously healthy man (Patient 1) and a 33-year-old woman with a past history of depression (Patient 2) developed neurological symptoms approximately 1 week after receipt of the first COVID-19 mRNA vaccination and deteriorated over the next week. Patient 1 reported nausea, headache, a high fever, and retrograde amnesia. Patient 2 reported visual disturbance, headache, dysarthria, a left forearm tremor, dysesthesia of the mouth and distal limbs, and visual agnosia. PCR test results for SARS-CoV-2 were negative. Complete blood cell count, biochemistry, and antibody test and cerebrospinal fluid test findings were unremarkable. Diffusion-weighted and fluid-attenuated inversion recovery MRI of the brain showed a high signal intensity lesion at the midline of the splenium of the corpus callosum compatible with cytotoxic lesions of the corpus callosum (CLOCCs). High-dose intravenous methylprednisolone improved their symptoms and imaging findings. CLOCCs should be considered in patients with neurological manifestation after COVID-19 vaccination.

Keywords Coronavirus disease 2019 · COVID-19 · Cytotoxic lesions of the corpus callosum · Mild encephalitis/encephalopathy with a reversible splenial lesion · COVID-19 mRNA vaccine

Introduction
Various neurological adverse events can occur after coronavirus disease 2019 (COVID-19) vaccination. According to a prior study of healthcare workers, 98.34% of those who received the mRNA-1273 vaccination (Moderna) had unpleasant symptoms and 61.2% of them had trouble doing everyday activities [1]. As for the BNT162b2 vaccine (Pfizer-BioNTech), 20.3% of the recipients had troubles in activities of daily living [2]. Headache, dizziness, decreased appetite, muscle spasm, decreased sleep quality, and brain fogging were the most commonly reported symptoms relevant to the central nervous system [1, 2]. The etiology of adverse reaction to COVID-19 vaccines has not been fully elucidated. Though these symptoms are not life-threatening, they have significant impact on social unrest over unknown

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| COVID-19 | Coronavirus disease 2019 |
| CLOCCs | Cytotoxic lesions of the corpus callosum |
| MERS | Mild encephalitis/encephalopathy with a reversible splenial lesion |
| MRI | Magnetic resonance imaging |
| DWI | Diffusion weighted imaging |
| ADC | Apparent diffusion coefficient |

PCR | Reverse transcription polymerase chain reaction test |
SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
CSF | Cerebrospinal fluid |
IL | Interleukin |

*Masako Kinoshita
machak@kuhp.kyoto-u.ac.jp

1 Department of Neurology, Minaminara General Medical Center, Yoshino, Nara, Japan
2 Department of Neurology, Nara Medical University School of Medicine, Kashihara, Nara, Japan
3 Department of Infection, Minaminara General Medical Center, Yoshino, Nara, Japan
4 Department of Biomedical Engineering, Faculty of Engineering, University of Malaya, Kuala Lumpur, Malaysia
5 Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tamil Nadu, India
6 Department of Neurology, National Hospital Organization Utano National Hospital, 8 Ondoyama-cho, Narutaki, Ukyo-ku, Kyoto 616-8255, Japan
Various clinical conditions are associated with cytotoxic lesions of the corpus callosum (CLOCCs) [3]. In the early stages, CLOCCs were described in patients with epileptic seizures treated with antiepileptic medications [4]. The condition was named as mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) in 2004, characterized by an ovoid lesion at the midline of the splenium of the corpus callosum in patients without preceding epilepsy or viral infection as well [5]. Neurological manifestations of MERS include confusion, delirium, and seizures. Usually, they were considered as a relatively mild syndrome that resolved within a month [5–7]. Then, cumulative data revealed that the splenic lesion can be caused by a variety of diseases and conditions, some of which have a terrible prognosis [3, 8]. These lesions have been called by different names including “MERS”, “reversible splenial lesion syndrome”, “reversible splenial lesions”, “transient splenial lesions”, “clinically silent lesions in the splenium of the corpus callosum,” and “transient focal lesions in the splenium of the corpus callosum.” Recently, Starkey et al. termed these lesions as CLOCCs because restricted diffusion with low apparent diffusion coefficient (ADC) value indicates cytotoxic edema [3].

Previous reports demonstrated Japanese children with the splenic lesion after mumps vaccination [9]. In this study, we investigated the clinical features of the two cases with CLOCCs presenting neurological symptoms after receiving COVID-19 vaccination.

Case presentation

Two adult patients, who developed neurological symptoms approximately 1 week after receipt of the first standard dose (0.3 mL, intramuscular injection) of COVID-19 mRNA vaccination (COMIRNATY intramuscular injection, Pfizer-BioNTech) (Day 1) and deteriorated over the next week, were included. Clinical course, laboratory, and MRI findings were serially analyzed. This study was carried out in accordance with the Declaration of Helsinki and was exempted from institutional ethics committee approval. Written informed consent was obtained from the patients for the publication of the case report and any accompanying images.

Patient 1

A 23-year-old man presented with nausea, mild headache, and low-grade fever (37.5 °C) (Day 9). He had no previous history of major illness and took no medication. He was a never-smoker. Neurological examination, complete blood cell count, blood chemistry including electrolytes and antibody titers, and brain magnetic resonance imaging (MRI) were unremarkable. Blood coagulation system including D-dimer was not examined. Reverse transcription polymerase chain reaction test (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was negative. Cerebrospinal fluid (CSF) test showed pleocytosis (102 cells/µL (monocyte count 12 cells/µL, polycyte count 90 cells/µL), normal ≤ 5 cells/µL). Under the suspicion of aseptic meningitis, he was given intravenous acyclovir (750 mg/day) and meropenem (6.0 g/day). However, his body temperature increased up to 40 °C and he became confused, disoriented, and amnestic on Day 14. CSF test on Day 16 showed increased number of cells (942 cells/µL (monocyte count 126 cells/µL, polycyte count 816 cells/µL)) and elevated protein levels (181 mg/dL, normal 10–40 mg/dL). Interleukin (IL)-6 was markedly elevated in the CSF on Day 16 (429.0 pg/mL, cut-off value 4.3 pg/mL [10]) but normal in the serum on Day 17 (5.4 pg/mL, normal ≤ 7 pg/mL). Brain MRI on Day 18 showed an ovoid restricted diffusion in diffusion weighted imaging (DWI) in the splenium with low apparent diffusion coefficient (ADC) values (Fig. 1). Contrast-enhanced MRI was not obtained. Based on the typical imaging features, he was diagnosed with CLOCCs. Additional therapy with intravenous high-dose methylprednisolone (2 courses of 1,000 mg/day for 3 days; Day 18–Day 20 and Day 24–Day 26) was effective. On Day 25, the splenial lesion disappeared (Fig. 1). He completely recovered on Day 26, and afterwards, no residual symptoms or recurrence was found during follow-up period of 8 months.
symptoms gradually recovered over the next month. Thereafter, no recurrence occurred during follow-up period of 7 month.

Discussion

To the best of our knowledge, this is the first report of neurological manifestations with CLOCCs that occurred approximately 1 week after COVID-19 vaccination. Thus far, 2 case reports showed that CLOCCs emerged 2 or 3 days after COVID-19 vaccination [11, 12]. On the other hand, Patient 1 in our study demonstrated that MRI on Day 9 was negative for the splenial lesion and CLOCCs was noticed on Day 18, and IL-6 elevation in the CSF. Clinical course of both Patients 1 and 2 showed subacute progression over weeks and effectiveness of immunotherapy. The findings shed light on possible role of delayed immune response with cytokine storm in long-lasting neurological symptoms associated with COVID-19 vaccination and even with COVID-19 itself, and need for immunomodulation and immunosuppression therapies.

An ovoid lesion in the midline of the splenium, not accompanied by any other imaging abnormality, has been associated with preexisting epilepsy under antiepileptic treatment and viral infection. Tada et al. investigated clinical features of 15 patients with new onset encephalitis/encephalopathy with reversible splenial lesion and reported that the patients showed relatively mild neurological manifestations and completely recovered in 1 month [5]. As per the national survey of pediatric acute encephalopathy in Japan, CLOCCs is the second most frequent syndrome (215 cases, 19.3%), and is most commonly associated with influenza virus [13]. Besides intracranial direct viral infection, hemodynamic, metabolic, electrolyte, or autoimmunity are possible mechanism of CLOCCs.

CLOCCs after vaccination are relatively uncommon. Only five male youngsters have developed CLOCCs after mumps immunization so far [9]. All 5 patients showed hyponatremia, and mumps vaccine virus (Hoshino strain and Torii strain) was confirmed in their CSF. In contrast,
hyponatremia or other electrolyte imbalances were not detected in our patients. SARS-CoV-2 infection was also unlikely based on negative PCR result. Recently, increased cytokines/chemokines were demonstrated in patients with MERS associated with acute focal bacterial nephritis, which were normalized in several weeks [14]. In the current study, Patient 1 showed marked elevation of CSF IL-6 level according to cut-off value of lupus psychosis [10]. Therefore, possible role of cytokine storm in neurological symptoms associated with COVID-19 vaccination and even with COVID-19 itself should be further elucidated [15]. Information on other cytokines such as IL-8, IL-1α, and tumor necrosis factor-α would be helpful to investigate autoimmune mechanism in the central nervous system. Serum level of IL-6 was within normal limit in both of our patients; thus, CSF test would be necessary. Contrast-enhanced MRI is useful to exclude acute disseminated encephalomyelitis though sole involvement of corpus callosum is rare [16].

Though neurological manifestations of CLOCCs are mild and can be reversible, patients with overt disturbance or alteration of consciousness, focal neurological deficits, or seizures, especially with progression as in our cases, are treated with steroids and immunoglobulin [3, 5, 9, 13, 14].

Conclusions

In conclusion, CLOCCs should be considered in patients who had neurological symptoms after receiving COVID-19 vaccination, even if the symptoms were mild and nonspecific.

Funding

This study was partially supported by JPJSBP 120217720.

Data availability

The data that support the findings of this study are available on request from the first author (H. O.). The data are not publicly available due to information that could compromise research participant privacy.

Declarations

Competing interests

The authors declare no competing interests.
**Ethics approval and consent to participate** The examinations were performed as a part of an intensive clinical evaluation. On the basis of the noninvasive case-accumulation study design with assured anonymity, the current study was exempt from the need for the institutional ethics committee approval.

**Consent for publication** Written informed consent was obtained from the patients.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Kadali RAK, Janagama R, Peruru S et al (2021) Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 93:4420–4429. https://doi.org/10.1002/jmv.26996
2. Kadali RAK, Janagama R, Peruru S, Malayala SV (2021) Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 106:376–381. https://doi.org/10.1016/j.ijid.2021.04.047
3. Starkey J, Kobayashi N, Numaguchi Y, Moritani T (2017) Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics 37:562–576. https://doi.org/10.1148/rg.2017160085
4. Kim SS, Chang KH, Kim ST et al (1999) Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol 20:125–129
5. Tada H, Takanashi J, Barkovich AJ et al (2004) Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 63:1854–1858. https://doi.org/10.1212/01.wnl.0000144274.12174.cb
6. Maeda M, Tsukahara H, Terada H et al (2006) Reversible splenial lesion with restricted diffusion in a wide spectrum of diseases and conditions. J Neuroradiol 200633:229–236. https://doi.org/10.1016/s0150-9861(06)77268-6
7. Zhang Z, Guo J, Li X, Li C, Ma X, Cui X (2020) Mild encephalitis/encephalopathy with a reversible isolated splenial lesion (MERS) in adult patients: a small case series. Eur Neurol 83:279–286. https://doi.org/10.1159/000090349
8. Zhu Y, Zheng J, Zhang L et al (2016) Reversible splenial lesion syndrome associated with encephalitis/encephalopathy presenting with great clinical heterogeneity. BMC Neurol 16:49. https://doi.org/10.1186/s12883-016-0572-9
9. Takanashi J, Shihiara T, Hasegawa T et al (2015) Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination. J Neurol Sci 349:226–228. https://doi.org/10.1016/j.jns.2014.12.019
10. Hirohata S, Kanai Y, Mitsu A, Tokano Y, Hashimoto H, NPSLE Research Subcommittee (2009) Accuracy of cerebrospinal fluid IL testing for diagnosis of lupus psychosis A multicenter retrospective study. Clin Rheumatol 28:1319–1323. https://doi.org/10.1007/s10067-009-1226-8
11. Youn T, Yang H (2021) Cytotoxic lesion of the corpus callosum (CLOCCs) after SARS-CoV-2 mRNA Vaccination. J Korean Med Sci 36:e228. https://doi.org/10.3346/jkms.2021.36.e228
12. Poussaint TY, LaRovere KL, Newburger JW et al (2021) Multisystem inflammatory-like syndrome in a child following COVID-19 mRNA vaccination. Vaccines (Basel) 10:43. https://doi.org/10.3390/vaccines10010043
13. Kasai M, Shibata A, Hoshino A et al (2020) Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014–2017. Brain Dev 42:508–514. https://doi.org/10.1016/j.braindev.2020.04.006
14. Okada T, Fujita Y, Imataka G et al (2022) Increased cytokines/chemokines and hyponatremia as a possible cause of clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with acute focal bacterial nephritis. Brain Dev 44:30–35. https://doi.org/10.1016/j.braindev.2021.07.008
15. Kappelmann N, Dantzer R, Khandaker GM (2021) Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology 131:105295. https://doi.org/10.1016/j.psyneuen.2021.105295
16. Banwell B, Shroff M, Ness JM et al (2007) MRI features of pediatric multiple sclerosis. Neurology 68:S46–S53. https://doi.org/10.1212/01.wnl.0000259406.09052.75

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.